RT Journal Article
SR Electronic
T1 Antiemetic effect of pregabalin in breast reconstruction surgery in patients after bariatric surgery: Prospective, randomized, double-blind study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.20.23292941
DO 10.1101/2023.07.20.23292941
A1 Fernandes, Rafael Reis
A1 Salgado-Filho, Marcello Fonseca
A1 Graziosi, Guilherme Bracco
A1 da Silva, André Luiz Viana Nery
A1 Távora, Flávio Augusto Amaral Fernandes
A1 de Azevedo, Caio Pontes
A1 da Silva, Alice Ramos Oliveira
A1 Verçosa, Nubia
A1 Cavalcanti, Ismar Lima
YR 2023
UL http://medrxiv.org/content/early/2023/07/24/2023.07.20.23292941.abstract
AB Introduction Postoperative nausea and vomiting (PONV) is a common complication after general anesthesia. Pregabalin may reduce its incidence. The objective of this study was to evaluate the adjuvant antiemetic effect of pregabalin in the first 24 hours after surgery in patients undergoing breast reconstruction after bariatric surgery.Materials and Methods This prospective, randomized, double-blind study had 52 female patients aged between 18 and 64 years with physical status 1-2 of the American Society of Anesthesiologists who underwent breast reconstruction after bariatric surgery. The patients were divided into two groups. Patients in the control group received placebo, and those in the pregabalin group received 75 mg of pregabalin 2 hours before surgery and 75 mg 12 hours later. All patients received 4 mg dexamethasone and 4 mg ondansetron. The incidence of PONV was evaluated in the immediate postoperative period and 6 hours, 12 hours, and 24 hours later. The need for rescue doses of antiemetics and adverse events in the first 24 hours were recorded.Results The groups were homogeneous in clinical and treatment variables. There was no significant difference in the incidence of PONV over time in the control group (P = 0.71/no occurrence) or in the pregabalin group (P = 0.11/P = 0.26). There was no significant difference in the need for rescue antiemetic dose (P = 0.40) or in the incidence of adverse events (P = 0.51) between groups.Conclusion The administration of pregabalin in the first 24 hours after surgery did not significantly reduce PONV in patients undergoing breast reconstruction after bariatric surgery.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialUTN code: U1111-1259-6153.Clinical ProtocolsN/A.Funding StatementThe author receive no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee in human research of the Antônio Pedro University Hospital, Niterói, Rio de Janeiro, Brazil, CAAE: 85415718.2.0000.5243.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files.N/A.